Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors

Chromogranin A (CgA), present in the chromaffin granules of neuroendocrine cells, is a useful biomarker for the diagnosis of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This study was conducted to investigate the potential role of circulating CgA in monitoring clinical res...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-05, Vol.11 (5), p.e0154679
Main Authors: Tian, Tiantian, Gao, Jing, Li, Na, Li, Yanyan, Lu, Ming, Li, Zhongwu, Lu, Zhihao, Li, Jie, Shen, Lin
Format: Article
Language:English
Subjects:
Adult
Aged
Bioindicators
Biological markers
Biology and Life Sciences
Biomarkers
Biomarkers - blood
Cancer
Cancer metastasis
Cancer therapies
Care and treatment
Chemotherapy
Chromaffin granules
Chromogranin A - blood
Diagnosis
Education
Female
Granule cells
Hospitals
Humans
Laboratories
Liver
Male
Medical diagnosis
Medical prognosis
Medicine and Health Sciences
Metastases
Metastasis
Middle Aged
Monitoring
Neuroendocrine tumors
Neuroendocrine Tumors - blood
Neuroendocrine Tumors - pathology
Oncology
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - pathology
Patients
People and Places
Prognosis
Risk factors
Stomach Neoplasms - blood
Stomach Neoplasms - pathology
Survival Analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chromogranin A (CgA), present in the chromaffin granules of neuroendocrine cells, is a useful biomarker for the diagnosis of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This study was conducted to investigate the potential role of circulating CgA in monitoring clinical response in Chinese patients with advanced GEP-NETs. Eighty patients with advanced GEP-NETs treated in Peking University Cancer Hospital from September 2011 to May 2014 and 65 healthy individuals were included in this study. Serum CgA levels were analyzed for relationship with patient's baseline characteristics and clinical outcome. Median CgA levels were significantly higher in patients with advanced GEP-NETs than in healthy individuals (93.8 ng/mL vs. 37.1 ng/mL; P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0154679